Sun Pharmaceutical Q1 Results: Net profit falls 20% to Rs 2,278 crore; stock down 2%

Sun Pharmaceutical Industries on Thursday declared its financial performance for the first quarter of the current fiscal year.

In its Q1 earnings, the large-cap pharmaceutical firm reported a 19.64 per cent year-over-year decline in its consolidated net profit for the quarter ended June 30, 2025.

The company has posted a net profit of Rs 2,278.6 crore during the April–June quarter of this year, down from Rs 2,835.6 crore recorded in the same period last year.

Despite the decline in net profit, the company reported an increase in revenue from operations.

During the quarter, revenue increased by 9.47 per cent to Rs 13,851.4 crore in the first quarter of the current financial year, compared to Rs 12,652.75 crore during the corresponding period last year. While total income rose to Rs 14,315.8 crore from Rs 13,185.3 crore.

Meanwhile, EBITDA came in at Rs 4,302 crore for the quarter, an increase from Rs 3,608 crore in the previous year. The EBITDA margin rose to 31.06 per cent from 28.51 per cent.

Profit before tax for the quarter was Rs 3,172.8 crore, compared to Rs 3,423.5 crore in the year-ago period.

Total expenses stood at Rs 10,325.1 crore for the quarter, up from Rs 9,761.8 crore in the same quarter of the previous year.

Sun Pharma stock ends 2% lower
On Thursday, the company's stock ended almost 2 per cent lower to RS 1,700, apiece on the BSE.